An Initial Low-Dose Etelcalcetide Dosing Strategy in Hemodialysis Patients With Moderate Secondary Hyperparathyroidism is Effective and Cost-Saving
Overview
Overview
Authors
Authors
Affiliations
Affiliations
Soon will be listed here.
References
1.
Cunningham J, Block G, Chertow G, Cooper K, Evenepoel P, Iles J
. Etelcalcetide Is Effective at All Levels of Severity of Secondary Hyperparathyroidism in Hemodialysis Patients. Kidney Int Rep. 2019; 4(7):987-994.
PMC: 6611952.
DOI: 10.1016/j.ekir.2019.04.010.
View
2.
Bushinsky D, Chertow G, Cheng S, Deng H, Kopyt N, Martin K
. One-year safety and efficacy of intravenous etelcalcetide in patients on hemodialysis with secondary hyperparathyroidism. Nephrol Dial Transplant. 2019; 35(10):1769-1778.
PMC: 7538239.
DOI: 10.1093/ndt/gfz039.
View
3.
Tentori F, Wang M, Bieber B, Karaboyas A, Li Y, Jacobson S
. Recent changes in therapeutic approaches and association with outcomes among patients with secondary hyperparathyroidism on chronic hemodialysis: the DOPPS study. Clin J Am Soc Nephrol. 2014; 10(1):98-109.
PMC: 4284424.
DOI: 10.2215/CJN.12941213.
View
4.
Dorr K, Kammer M, Reindl-Schwaighofer R, Lorenz M, Prikoszovich T, Marculescu R
. Randomized Trial of Etelcalcetide for Cardiac Hypertrophy in Hemodialysis. Circ Res. 2021; 128(11):1616-1625.
DOI: 10.1161/CIRCRESAHA.120.318556.
View
5.
Karaboyas A, Muenz D, Fuller D, Desai P, Lin T, Robinson B
. Etelcalcetide Utilization, Dosing Titration, and Chronic Kidney Disease-Mineral and Bone Disease (CKD-MBD) Marker Responses in US Hemodialysis Patients. Am J Kidney Dis. 2021; 79(3):362-373.
DOI: 10.1053/j.ajkd.2021.05.020.
View